Format

Send to

Choose Destination
Cancer Invest. 2018 Mar 16;36(3):190-198. doi: 10.1080/07357907.2018.1449212. Epub 2018 Mar 22.

Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma.

Author information

1
a Department of Obstetrics and Gynecology , Columbia University College of Physicians and Surgeons , New York , USA.
2
d Herbert Irving Comprehensive Cancer Center , Columbia University College of Physicians and Surgeons , New York , New York , USA.
3
e New York Presbyterian Hospital , New York , New York , USA.
4
c Department of Epidemiology, Joseph L. Mailman School of Public Health , Columbia University , New York , New York , USA.
5
b Department of Medicine , Columbia University College of Physicians and Surgeons , New York , New York , USA.

Abstract

We analyzed 54,039 women with uterine cancer in the National Cancer Database from 2013 to 2014 including 38,453 (71.2%) who underwent lymphadenectomy, 1929 (3.6%) who underwent sentinel lymph node (SLN) mapping, and 13,657 (25.3%) who did not undergo nodal assessment. SLN mapping increased from 2.8% in 2013 to 4.3% in 2014 (P < 0.001). Patients treated in 2014 and those at community centers were more likely to undergo SLN biopsy, while women with advanced-stage disease, sarcomas, and grade 3 tumors were less likely to undergo SLN mapping (P < 0.05). There was no association between use of SLN biopsy and use of radiation (aRR = 0.92; 95% CI, 0.82-1.05).

KEYWORDS:

Endometrial cancer; Hysterectomy; Lymphadenectomy; Sentinel lymph node; Uterine cancer

PMID:
29565689
PMCID:
PMC6291832
DOI:
10.1080/07357907.2018.1449212
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center